The 36-month beta value for DAWN is at -1.44. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 5 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for DAWN is 73.84M, and currently, shorts hold a 23.42% of that float. The average trading volume for DAWN on February 26, 2025 was 971.40K shares.
DAWN) stock’s latest price update
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) has seen a decline in its stock price by -8.71 in relation to its previous close of 11.82. However, the company has experienced a -8.40% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-02-26 that Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Joey Perrone – SVP, Finance and IR Jeremy Bender – CEO Lauren Merendino – CCO Charles York – COO and CFO Conference Call Participants Andrea Newkirk – Goldman Sachs Tara Bancroft – TD Cowen Joe Catanzaro – Piper Sandler Alec Stranahan – Bank of America Andres Maldonado – H.C. Wainwright Operator Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.
DAWN’s Market Performance
Day One Biopharmaceuticals Inc (DAWN) has experienced a -8.40% fall in stock performance for the past week, with a -15.51% drop in the past month, and a -19.12% drop in the past quarter. The volatility ratio for the week is 4.25%, and the volatility levels for the past 30 days are at 4.46% for DAWN. The simple moving average for the past 20 days is -11.12% for DAWN’s stock, with a -21.37% simple moving average for the past 200 days.
Analysts’ Opinion of DAWN
Many brokerage firms have already submitted their reports for DAWN stocks, with Needham repeating the rating for DAWN by listing it as a “Buy.” The predicted price for DAWN in the upcoming period, according to Needham is $33 based on the research report published on October 09, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see DAWN reach a price target of $24, previously predicting the price at $11. The rating they have provided for DAWN stocks is “Buy” according to the report published on August 01st, 2024.
Needham gave a rating of “Buy” to DAWN, setting the target price at $33 in the report published on April 24th of the previous year.
DAWN Trading at -12.49% from the 50-Day Moving Average
After a stumble in the market that brought DAWN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.29% of loss for the given period.
Volatility was left at 4.46%, however, over the last 30 days, the volatility rate increased by 4.25%, as shares sank -17.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.48% lower at present.
During the last 5 trading sessions, DAWN fell by -7.81%, which changed the moving average for the period of 200-days by -33.82% in comparison to the 20-day moving average, which settled at $12.14. In addition, Day One Biopharmaceuticals Inc saw -14.84% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DAWN starting from York Charles N II, who sale 4,370 shares at the price of $11.96 back on Feb 18 ’25. After this action, York Charles N II now owns 252,638 shares of Day One Biopharmaceuticals Inc, valued at $52,278 using the latest closing price.
Dubow Adam, the GENERAL COUNSEL of Day One Biopharmaceuticals Inc, sale 4,646 shares at $11.96 during a trade that took place back on Feb 18 ’25, which means that Dubow Adam is holding 39,602 shares at $55,580 based on the most recent closing price.
Stock Fundamentals for DAWN
Current profitability levels for the company are sitting at:
- -2.06 for the present operating margin
- 0.97 for the gross margin
The net margin for Day One Biopharmaceuticals Inc stands at -0.82. The total capital return value is set at -0.38. Equity return is now at value -17.84, with -16.61 for asset returns.
Based on Day One Biopharmaceuticals Inc (DAWN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -34.22.
Currently, EBITDA for the company is -217.27 million with net debt to EBITDA at 1.99. When we switch over and look at the enterprise to sales, we see a ratio of 6.12. The receivables turnover for the company is 11.79for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.62.
Conclusion
In conclusion, Day One Biopharmaceuticals Inc (DAWN) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
